US20070032856A1 - Drug eluting stent - Google Patents

Drug eluting stent Download PDF

Info

Publication number
US20070032856A1
US20070032856A1 US11/546,203 US54620306A US2007032856A1 US 20070032856 A1 US20070032856 A1 US 20070032856A1 US 54620306 A US54620306 A US 54620306A US 2007032856 A1 US2007032856 A1 US 2007032856A1
Authority
US
United States
Prior art keywords
strut
segment
coating
stent
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/546,203
Inventor
Timothy Limon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Cardiovascular Systems Inc
Original Assignee
Advanced Cardiovascular Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Cardiovascular Systems Inc filed Critical Advanced Cardiovascular Systems Inc
Priority to US11/546,203 priority Critical patent/US20070032856A1/en
Publication of US20070032856A1 publication Critical patent/US20070032856A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A61F2002/91516Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other the meander having a change in frequency along the band
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A61F2002/91533Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0004Rounded shapes, e.g. with rounded corners
    • A61F2230/0013Horseshoe-shaped, e.g. crescent-shaped, C-shaped, U-shaped
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir

Definitions

  • This invention relates to implantable medical devices, such as stents. More particularly, this invention relates to a stent having drug delivery capabilities.
  • Percutaneous transluminal coronary angioplasty is a procedure for treating heart disease.
  • a catheter assembly having a balloon portion is introduced into the cardiovascular system of a patient via the brachial or femoral artery.
  • the catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion.
  • the balloon is inflated to a predetermined size to radially compress against the atherosclerotic plaque of the lesion to remodel the lumen wall.
  • the balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.
  • a problem associated with the procedure includes formation of intimal flaps or torn arterial linings that can collapse and occlude the conduit after the balloon is deflated. Moreover, thrombosis and restenosis of the artery can develop over several months after the procedure, which can require another angioplasty procedure or a surgical bypass operation.
  • an intraluminal prosthesis is implanted in the lumen to maintain the vascular patency.
  • Stents are scaffolding structures, usually cylindrical or tubular in shape, functioning to physically hold open, and if desired, to expand the wall of the passageway. Typically stents are capable of being compressed for insertion through small cavities via small catheters, and then expanded to a larger diameter once at the desired location.
  • One commonly applied technique for the local delivery of the drugs is through the use of medicated stents.
  • One method of medicating stents involves the use of a polymeric carrier coated onto the body of the stent. A polymer dissolved in a solvent and a drug added thereto can be applied to the stent. Once the solvent evaporates, a coating of the polymer containing the drug remains on the stent.
  • the embodiments of the present invention provide various stent structures for containing a coating, such as a polymeric coating, for the local delivery of a drug.
  • a stent comprising a strut having a first segment, a second segment and a third segment located between the first and second segments, wherein the transverse cross sectional area of the third segment is less than the transverse cross sectional area of the first segment and the second segment; and a coating disposed on the third segment of the strut, wherein the first and second segments of the strut are free of any coating.
  • the coating is disposed all the way around the third segment of the strut. The outer surface of the coating should not extend beyond the outer surface of the first or second segment of the strut.
  • the coating can be made from a polymeric material containing a therapeutic substance.
  • the strut includes a linear segment extending into a curved segment, wherein the first, second and third segments define a part of the linear segment of the strut.
  • the curved segment can include a notch or can be smaller in thickness or width than the first or second segment of the strut.
  • a radially expandable stent comprising a strut, at least a segment of the strut having a circumference smaller than the circumference of a remaining portion of the strut; and a coating supported by the segment of the strut having the smaller circumference.
  • the strut can include four sides, wherein the width of the segment of the strut having the smaller circumference is less than the width of the remaining portion of the strut.
  • the thickness of the segment of the strut having the smaller circumference is less than the thickness of the remaining portion of the strut.
  • the coating can, for example, surround the segment of the strut having the reduced circumference. The remaining portion of the strut having the larger circumference can be free from any coating.
  • a method of manufacturing a drug eluting stent comprising depositing a coating on a first segment of a strut of the stent, the stent including a second segment and a third segment, wherein the first segment is positioned between the second segment and the third segment, the first segment having a smaller transverse cross sectional area than the transverse cross sectional area of the second or third segment.
  • a method of manufacturing a drug eluting stent comprising depositing a coating on a stent, the stent including a strut having a first segment, a second segment, and a third segment located between the first and second segments, wherein the transverse cross sectional area of the third segment is less than the transverse cross sectional area of the first segment and the second segment; and removing the coating off of the first and second segments so that the coating remains on the third segment.
  • FIG. 1 illustrates an embodiment of a conventional stent
  • FIG. 2 is an enlarged perspective view of the stent strut of encircled region 2 of FIG. 1 ;
  • FIGS. 2A and 2B are transverse cross sectional views along the line 2 A- 2 A and 2 B- 2 B, respectively, of FIG. 2 ;
  • FIGS. 3, 4 , 5 , 6 A, and 6 B are perspective views of a stent strut according to other embodiments of the invention.
  • FIG. 1 illustrates one embodiment of a stent 10 that can be used with the practice of the present invention.
  • Stent 10 can be generally cylindrical and radially self- or balloon-expandable. Stent 10 can be inserted and deployed in a patient with an appropriate delivery device such as a balloon dilatation catheter.
  • Stent 10 can be made, for example, from a plurality of wave-like or serpentine-like struts 12 having curved segments and generally linear segments. Struts 12 are connected to the adjacent struts 12 via connecting elements 14 .
  • the embodiments of the present invention should not be limited to the structure of FIG. 1 .
  • a variety of other scaffolding designs can also be used, such as “V” shaped struts or Struts having a “zigzag” formation.
  • the linear section of strut 12 includes a segment, referred to by reference number 16 , wherein any transverse cross sectional portion of segment 16 has a smaller cross sectional surface area than the remaining segment of strut 12 .
  • FIG. 2A illustrates a transverse cross sectional view of strut 12 of FIG. 2 taken along the line 2 A- 2 A.
  • FIG. 2B illustrates a transverse cross sectional view of strut 12 of FIG. 2 taken along the line 2 B- 2 B.
  • segment 16 has a reduced thickness and width, which provides for a smaller circumference, as compared to the remaining portions of strut 12 .
  • FIGS. 2, 2A and 2 B illustrate a four-sided strut 12 wherein segment 16 has a reduced width W as well as thickness T.
  • Struts 12 need not be four-sided, however, and can have any suitable transverse cross sectional geometry, such as a three sided, oval or circular struts.
  • the reduced circumferential size of segment 16 defines a recessed volume 18 in which a coating 20 can be deposited.
  • Coating 20 can be a drug or a therapeutic composition or can contain the drug.
  • Coating 20 can be made from any suitable biocompatible polymer, examples of which are disclosed below.
  • the remaining segments of strut 12 can be free from any substances or coatings.
  • Coating 20 can be disposed all the way around segment 16 as coating 20 can completely encapsulate the narrowed segment 16 of strut 12 .
  • Recessed volume 18 can be fully filled with the coating substance such that the outer surfaces of coating 20 are “flush” with their respective outer surfaces of strut 12 .
  • the outer dimensions of coating 20 can equal the outer dimensions of strut 12 , thereby creating a smooth transition between the surfaces of coating 20 and the surfaces of strut 12 , thus minimizing intravascular flow turbulence around stent 10 .
  • strut 12 can have a variable thickness T, but a constant width W. As best illustrated by FIG. 3 , width W of strut 12 is the same, but thickness T is reduced along segment 16 of strut 12 . The reduced thickness T provides recessed volume 18 containing coating 20 on the outer surface or tissue-contacting surface of strut 12 . Although not illustrated, a recessed volume 18 can also be provided in the inner or lumen surface of strut 12 .
  • a variable width W for strut 12 can be provided, while maintaining the thickness T constant.
  • thickness T of strut is the same, but width W is reduced along segment 16 of strut 12 .
  • FIG. 4 illustrates recessed volumes 18 on opposing sides of strut 12 .
  • recessed volume 18 can be about only one of the two sides of strut 12 .
  • Transition zones leading into segment 16 can be gradual, with a slight slop, as illustrated by FIG. 2 or can be a relatively sharp drop-off, as illustrated by FIG. 3 or 4 .
  • the smallest transverse cross sectional area in segment 16 can be up to about 50% smaller than the transverse cross sectional area of the remaining portions of strut 12 .
  • One having ordinary skill in the art should be cautious of mechanical fatigue and failure that could be caused if the circumference of segment 16 is too small or if the transition zone is sloped too non-compliant.
  • Exemplary dimensions and design of strut 12 depend, of course, on an variety of factors including the material from which strut 12 is made, the length of segment 16 , and the application for which stent 10 will be used. Accordingly, there is a tradeoff between trying to maximize recess volume 18 for maximizing drug delivery capabilities and eliminating mechanical failure that can be caused by radial expansion and use of stent 10 .
  • any number of suitable segments 16 having a reduced circumferential area can be included in strut 12 .
  • Having a multitude of segments 16 allows for the incorporation of more than one type of therapeutic substance in different areas of stent 10 . Accordingly, a variety of cocktail combinations of drugs can be delivered via stent 10 .
  • the longitudinal span of each segment 16 depends on the number of segments 16 that are to be incorporated into strut 12 and the length of strut 12 , among other factors.
  • FIG. 6A illustrates strut 12 having a thinned section, in either thickness or width, in the curved portion (as designated by reference number 22 ) of strut 12 .
  • notches 24 can be provided in curved portion 22 of strut 12 .
  • the thinned section and/or pivot notches 24 in curved portion 22 of strut 12 can produce a weakened bending region for stent 10 .
  • the weakened bending region can maximize bending along curved region 22 or at pivot notches 24 and minimize stress along the linear portion of strut 12 . This is advantageous in preserving the structural integrity of coating 20 so as to prevent or reduce fragmentation of coating during the radial expansion of stent 10 .
  • Struts 12 can be made from a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), “MP35N,” “MP20N,” ELASTINITE (nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co., Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Struts 12 can also be made fiom bioabsorbable or biostable polymers.
  • ELGILOY cobalt chromium alloy
  • stainless steel 316L
  • MP35N stainless steel
  • the drug, therapeutic substance or active agent, terms which are used interchangeably, in the coating 20 can inhibit the activity of vascular smooth muscle cells. More specifically, the active agent can be aimed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells for the inhibition of restenosis.
  • the active agent can also include any substance capable of exerting a therapeutic or prophylactic effect for a diseased condition.
  • the agent can be for enhancing wound healing in a vascular site or improving the structural and elastic properties of the vascular site.
  • agents include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich, Inc., Milwaukee, Wis.; or COSMEGEN available from Merck & Co., Inc., Whitehorse Station, N.J.). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I l , actinomycin X l , and actinomycin C l .
  • the active agent can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances.
  • antineoplastics and/or antimitotics examples include paclitaxel (e.g., TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g., Taxotere®, from Aventis S.A., Frankfurt, Germany), methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g., Adriamycin® from Pharmacia & Upjohn, Peapack, N.J.), and mitomycin (e.g., Mutamycin® from Bristol-Myers Squibb Co.).
  • paclitaxel e.g., TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.
  • docetaxel e.g., Taxotere®, from Aventis S.A., Frankfurt, Germany
  • methotrexate e.g., azathio
  • antiplatelets examples include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as Angiomax ä (Biogen, Inc., Cambridge, Mass.).
  • cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co.), cilazapril or lisinopril (e.g., Prinivil® and Prinzide® from Merck & Co., Inc.); calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids,
  • Coating 20 can be made from any suitable biocompatible polymer, examples of which include ethylene vinyl alcohol copolymer (commonly known by the generic name EVOH or by the trade name EVAL); poly(hydroxyvalerate); poly(L-lactic acid); polycaprolactone; poly(lactide-co-glycolide); poly(hydroxybutyrate); poly(hydroxybutyrate-co-valerate); polydioxanone; polyorthoester; polyanhydride; poly(glycolic acid); poly(D,L-lactic acid); poly(glycolic acid-co-trimethylene carbonate); polyphosphoester; polyphosphoester urethane; poly(amino acids); cyanoacrylates; poly(trimethylene carbonate); poly(iminocarbonate); copoly(ether-esters) (e.g., PEO/PLA); polyalkylene oxalates; polyphosphazenes; biomolecules, such as fibrin, fibrinogen, cellulose, starch, collagen
  • Stent 10 can be constructed, for example, from a tube of a desired strut material.
  • the tube can be mounted onto a mandrel and angular grooves can be cut into the outer surface of the tube by a lathe or a Swiss screw, for example KJR-16Swiss Screw Machine available from STAR CNC Automatic Lathe in Shizuoka, Japan.
  • the shape of strut 12 can then be radially cut from the tube by a laser.
  • the laser cutting can also produce the thinned curved section 22 or pivot notches 24 illustrated in FIGS. 6A and 6B .
  • Struts 12 can be electropolished to reshape or round off sharp comers.
  • Stent 10 can then be mounted on a Teflon® or paralyne coated mandrel fixed to a two-dimensional actuator controlled by a computer numerical control (CNC) controller, for example a Model DR500available from Aerotek, Inc., Pittsburgh, Pa.
  • CNC computer numerical control
  • the two-dimensional actuator can translate and rotate stent 10 about the longitudinal axis of stent 10 .
  • a fluid applicator device for example a Model 1500XL available from EFD, Inc., East Buffalo, R.I., with a needle tip, can be fixed adjacent to the mounted stent 10 and ejection of a coating substance can be controlled by the CNC controller.
  • the needle tip can have an outer diameter of about 0.02 mm (0.0008in.) to about 0.038 mm (0.0015 in.) and an inner diameter from about 0.005 mm (0.0002 in.) to about 0.02 mm (0.0009 in.).
  • the CNC controller then causes ejection of coating 20 in a liquid state from the needle tip into recessed volume 18 and simultaneously moves stent 10 longitudinally to spread coating 20 evenly in recessed volume 18 .
  • recessed volume 18 of segment 16 is coated with a desired volume of coating 20
  • ejection of the coating substance ceases and stent 10 can be moved until the next uncoated recessed volume 18 is adjacent to the needle tip of the fluid applicator device.
  • the process can repeat until all the recessed volumes 18 are coated.
  • the needle tip should also be capable of being raised and lowered relative to stent 10 by the CNC controller particularly when coating small volumes necessitates direct contact between the needle tip and stent 10 .
  • coating 20 can be deposited in recessed volumes 18 by crimping stent 10 onto a mandrel covered with a soft material (for examples, having a D hardness rating of about 20 to about 50, such as silicon foam, neoprene, santoprene, or a closed cell foam).
  • a soft material for examples, having a D hardness rating of about 20 to about 50, such as silicon foam, neoprene, santoprene, or a closed cell foam.
  • the soft material can have, for example, a soft material thickness of at least the thickness of strut 12 .
  • the mandrel and stent 10 can then be dipped into the coating substance or the coating substance can be sprayed onto stent 10 .
  • the mandrel and stent 10 can then be pulled through an orifice with a clearance around strut 12 of less than about 0.003 mm (0.0001 in.), more narrowly less than about 0.001 mm (0.00005 in.). Stent 10 can also be pulled over a reamer to scrape off excess coating substance.
  • masking techniques as is known to a person having ordinary skill in the art can be used to deposit coating 20 in recessed volumes 18 of segment 16 .

Abstract

Stents having struts with narrowed portions are described. The narrowed portions have a coating disposed thereon for the local delivery of a drug.

Description

    CROSS REFERENCE TO RELATED APPLICATION
  • This is a divisional application of U.S. patent application Ser. No. 10/262,150, which was filed on Sep. 30, 2002.
  • BACKGROUND
  • This invention relates to implantable medical devices, such as stents. More particularly, this invention relates to a stent having drug delivery capabilities.
  • Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart disease. A catheter assembly having a balloon portion is introduced into the cardiovascular system of a patient via the brachial or femoral artery. The catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress against the atherosclerotic plaque of the lesion to remodel the lumen wall. The balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.
  • A problem associated with the procedure includes formation of intimal flaps or torn arterial linings that can collapse and occlude the conduit after the balloon is deflated. Moreover, thrombosis and restenosis of the artery can develop over several months after the procedure, which can require another angioplasty procedure or a surgical bypass operation. To reduce the partial or total occlusion of the artery by the collapse of arterial lining and to reduce the chance of the development of thrombosis and restenosis, an intraluminal prosthesis, an example of which includes an expandable stent, is implanted in the lumen to maintain the vascular patency. Stents are scaffolding structures, usually cylindrical or tubular in shape, functioning to physically hold open, and if desired, to expand the wall of the passageway. Typically stents are capable of being compressed for insertion through small cavities via small catheters, and then expanded to a larger diameter once at the desired location.
  • To treat the damaged vasculature tissue and further fight against thrombosis and restenosis, there is a need to administer therapeutic substances to the treatment site. For example, anticoagulants, antiplatelets and cytostatic agents are commonly used to prevent thrombosis of the coronary lumen, to inhibit development of restenosis, and to reduce post-angioplasty proliferation of the vascular tissue. To provide an efficacious concentration to the treated site, systemic administration of medication can produce adverse or toxic side effects for the patient. Local delivery is a highly suitable method of treatment in that smaller levels of medication, as compared to systemic dosages, are concentrated at a specific site. Local delivery produces fewer side effects and achieves more effective results.
  • One commonly applied technique for the local delivery of the drugs is through the use of medicated stents. One method of medicating stents involves the use of a polymeric carrier coated onto the body of the stent. A polymer dissolved in a solvent and a drug added thereto can be applied to the stent. Once the solvent evaporates, a coating of the polymer containing the drug remains on the stent. The embodiments of the present invention provide various stent structures for containing a coating, such as a polymeric coating, for the local delivery of a drug.
  • SUMMARY
  • In accordance with one embodiment, a stent is disclosed comprising a strut having a first segment, a second segment and a third segment located between the first and second segments, wherein the transverse cross sectional area of the third segment is less than the transverse cross sectional area of the first segment and the second segment; and a coating disposed on the third segment of the strut, wherein the first and second segments of the strut are free of any coating. In one embodiment, the coating is disposed all the way around the third segment of the strut. The outer surface of the coating should not extend beyond the outer surface of the first or second segment of the strut. The coating can be made from a polymeric material containing a therapeutic substance. In accordance with one embodiment, the strut includes a linear segment extending into a curved segment, wherein the first, second and third segments define a part of the linear segment of the strut. The curved segment can include a notch or can be smaller in thickness or width than the first or second segment of the strut.
  • In accordance with another embodiment of the invention, a radially expandable stent is provided comprising a strut, at least a segment of the strut having a circumference smaller than the circumference of a remaining portion of the strut; and a coating supported by the segment of the strut having the smaller circumference. The strut can include four sides, wherein the width of the segment of the strut having the smaller circumference is less than the width of the remaining portion of the strut. Alternatively, the thickness of the segment of the strut having the smaller circumference is less than the thickness of the remaining portion of the strut. The coating can, for example, surround the segment of the strut having the reduced circumference. The remaining portion of the strut having the larger circumference can be free from any coating.
  • In accordance with another embodiment of the invention, a method of manufacturing a drug eluting stent is provided, comprising depositing a coating on a first segment of a strut of the stent, the stent including a second segment and a third segment, wherein the first segment is positioned between the second segment and the third segment, the first segment having a smaller transverse cross sectional area than the transverse cross sectional area of the second or third segment.
  • In accordance with another embodiment of the invention, a method of manufacturing a drug eluting stent is provided, comprising depositing a coating on a stent, the stent including a strut having a first segment, a second segment, and a third segment located between the first and second segments, wherein the transverse cross sectional area of the third segment is less than the transverse cross sectional area of the first segment and the second segment; and removing the coating off of the first and second segments so that the coating remains on the third segment.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates an embodiment of a conventional stent;
  • FIG. 2 is an enlarged perspective view of the stent strut of encircled region 2 of FIG. 1;
  • FIGS. 2A and 2B are transverse cross sectional views along the line 2A-2A and 2B-2B, respectively, of FIG. 2; and
  • FIGS. 3, 4, 5, 6A, and 6B are perspective views of a stent strut according to other embodiments of the invention.
  • DETAILED DESCRIPTION
  • FIG. 1 illustrates one embodiment of a stent 10 that can be used with the practice of the present invention. Stent 10 can be generally cylindrical and radially self- or balloon-expandable. Stent 10 can be inserted and deployed in a patient with an appropriate delivery device such as a balloon dilatation catheter. Stent 10 can be made, for example, from a plurality of wave-like or serpentine-like struts 12 having curved segments and generally linear segments. Struts 12 are connected to the adjacent struts 12 via connecting elements 14. The embodiments of the present invention, however, should not be limited to the structure of FIG. 1. A variety of other scaffolding designs can also be used, such as “V” shaped struts or Struts having a “zigzag” formation.
  • Referring to FIG. 2, the linear section of strut 12 includes a segment, referred to by reference number 16, wherein any transverse cross sectional portion of segment 16 has a smaller cross sectional surface area than the remaining segment of strut 12. FIG. 2A illustrates a transverse cross sectional view of strut 12 of FIG. 2 taken along the line 2A-2A. FIG. 2B illustrates a transverse cross sectional view of strut 12 of FIG. 2 taken along the line 2B-2B. As illustrated by FIGS. 2A and 2B, segment 16 has a reduced thickness and width, which provides for a smaller circumference, as compared to the remaining portions of strut 12.
  • FIGS. 2, 2A and 2B illustrate a four-sided strut 12 wherein segment 16 has a reduced width W as well as thickness T. Struts 12 need not be four-sided, however, and can have any suitable transverse cross sectional geometry, such as a three sided, oval or circular struts. The reduced circumferential size of segment 16 defines a recessed volume 18 in which a coating 20 can be deposited. Coating 20 can be a drug or a therapeutic composition or can contain the drug. Coating 20 can be made from any suitable biocompatible polymer, examples of which are disclosed below. As best illustrated by FIG. 2, the remaining segments of strut 12 can be free from any substances or coatings. Coating 20 can be disposed all the way around segment 16 as coating 20 can completely encapsulate the narrowed segment 16 of strut 12. Recessed volume 18 can be fully filled with the coating substance such that the outer surfaces of coating 20 are “flush” with their respective outer surfaces of strut 12. In other words, the outer dimensions of coating 20 can equal the outer dimensions of strut 12, thereby creating a smooth transition between the surfaces of coating 20 and the surfaces of strut 12, thus minimizing intravascular flow turbulence around stent 10.
  • In accordance with another embodiment of the invention, as illustrated in FIG. 3, strut 12 can have a variable thickness T, but a constant width W. As best illustrated by FIG. 3, width W of strut 12 is the same, but thickness T is reduced along segment 16 of strut 12. The reduced thickness T provides recessed volume 18 containing coating 20 on the outer surface or tissue-contacting surface of strut 12. Although not illustrated, a recessed volume 18 can also be provided in the inner or lumen surface of strut 12.
  • In accordance with another embodiment, as illustrated by FIG. 4, a variable width W for strut 12 can be provided, while maintaining the thickness T constant. As best illustrated by FIG. 4, thickness T of strut is the same, but width W is reduced along segment 16 of strut 12. FIG. 4 illustrates recessed volumes 18 on opposing sides of strut 12. However, as is the case with FIG. 3, recessed volume 18 can be about only one of the two sides of strut 12.
  • Transition zones leading into segment 16 can be gradual, with a slight slop, as illustrated by FIG. 2 or can be a relatively sharp drop-off, as illustrated by FIG. 3 or 4. The smallest transverse cross sectional area in segment 16 can be up to about 50% smaller than the transverse cross sectional area of the remaining portions of strut 12. One having ordinary skill in the art should be cautious of mechanical fatigue and failure that could be caused if the circumference of segment 16 is too small or if the transition zone is sloped too non-compliant. Exemplary dimensions and design of strut 12 depend, of course, on an variety of factors including the material from which strut 12 is made, the length of segment 16, and the application for which stent 10 will be used. Accordingly, there is a tradeoff between trying to maximize recess volume 18 for maximizing drug delivery capabilities and eliminating mechanical failure that can be caused by radial expansion and use of stent 10.
  • In accordance with yet another embodiment, as illustrated in FIG. 5, any number of suitable segments 16 having a reduced circumferential area can be included in strut 12. Having a multitude of segments 16 allows for the incorporation of more than one type of therapeutic substance in different areas of stent 10. Accordingly, a variety of cocktail combinations of drugs can be delivered via stent 10. The longitudinal span of each segment 16 depends on the number of segments 16 that are to be incorporated into strut 12 and the length of strut 12, among other factors.
  • In accordance with yet another embodiment of the invention, FIG. 6A illustrates strut 12 having a thinned section, in either thickness or width, in the curved portion (as designated by reference number 22) of strut 12. Alternatively, as illustrated in FIG. 6B notches 24 can be provided in curved portion 22 of strut 12. The thinned section and/or pivot notches 24 in curved portion 22 of strut 12 can produce a weakened bending region for stent 10. The weakened bending region can maximize bending along curved region 22 or at pivot notches 24 and minimize stress along the linear portion of strut 12. This is advantageous in preserving the structural integrity of coating 20 so as to prevent or reduce fragmentation of coating during the radial expansion of stent 10.
  • Struts 12 can be made from a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), “MP35N,” “MP20N,” ELASTINITE (nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co., Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Struts 12 can also be made fiom bioabsorbable or biostable polymers.
  • The drug, therapeutic substance or active agent, terms which are used interchangeably, in the coating 20 can inhibit the activity of vascular smooth muscle cells. More specifically, the active agent can be aimed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells for the inhibition of restenosis. The active agent can also include any substance capable of exerting a therapeutic or prophylactic effect for a diseased condition. For example, the agent can be for enhancing wound healing in a vascular site or improving the structural and elastic properties of the vascular site. Examples of agents include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich, Inc., Milwaukee, Wis.; or COSMEGEN available from Merck & Co., Inc., Whitehorse Station, N.J.). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin Il, actinomycin Xl, and actinomycin Cl. The active agent can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances. Examples of such antineoplastics and/or antimitotics include paclitaxel (e.g., TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g., Taxotere®, from Aventis S.A., Frankfurt, Germany), methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g., Adriamycin® from Pharmacia & Upjohn, Peapack, N.J.), and mitomycin (e.g., Mutamycin® from Bristol-Myers Squibb Co.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as Angiomax ä (Biogen, Inc., Cambridge, Mass.). Examples of such cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co.), cilazapril or lisinopril (e.g., Prinivil® and Prinzide® from Merck & Co., Inc.); calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, rapamycin and its derivatives and analogs, and dexamethasone.
  • Coating 20 can be made from any suitable biocompatible polymer, examples of which include ethylene vinyl alcohol copolymer (commonly known by the generic name EVOH or by the trade name EVAL); poly(hydroxyvalerate); poly(L-lactic acid); polycaprolactone; poly(lactide-co-glycolide); poly(hydroxybutyrate); poly(hydroxybutyrate-co-valerate); polydioxanone; polyorthoester; polyanhydride; poly(glycolic acid); poly(D,L-lactic acid); poly(glycolic acid-co-trimethylene carbonate); polyphosphoester; polyphosphoester urethane; poly(amino acids); cyanoacrylates; poly(trimethylene carbonate); poly(iminocarbonate); copoly(ether-esters) (e.g., PEO/PLA); polyalkylene oxalates; polyphosphazenes; biomolecules, such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid; polyurethanes; silicones; polyesters; polyolefins; polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers and copolymers; vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile; polyvinyl ketones; polyvinyl aromatics, such as polystyrene; polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers; polyamides, such as Nylon 66 and polycaprolactam; alkyd resins; polycarbonates; polyoxymethylenes; polyinides; polyethers; epoxy resins; polyurethanes; rayon; rayon-triacetate; cellulose; cellulose acetate; cellulose butyrate; cellulose acetate butyrate; cellophane; cellulose nitrate; cellulose propionate; cellulose ethers; and carboxymethyl cellulose. Coating 20 can also be silicon foam, neoprene, santoprene, or closed cell foam.
  • Stent 10 can be constructed, for example, from a tube of a desired strut material. The tube can be mounted onto a mandrel and angular grooves can be cut into the outer surface of the tube by a lathe or a Swiss screw, for example KJR-16Swiss Screw Machine available from STAR CNC Automatic Lathe in Shizuoka, Japan. The shape of strut 12 can then be radially cut from the tube by a laser. The laser cutting can also produce the thinned curved section 22 or pivot notches 24 illustrated in FIGS. 6A and 6B. Struts 12 can be electropolished to reshape or round off sharp comers.
  • Stent 10 can then be mounted on a Teflon® or paralyne coated mandrel fixed to a two-dimensional actuator controlled by a computer numerical control (CNC) controller, for example a Model DR500available from Aerotek, Inc., Pittsburgh, Pa. The two-dimensional actuator can translate and rotate stent 10 about the longitudinal axis of stent 10. A fluid applicator device, for example a Model 1500XL available from EFD, Inc., East Providence, R.I., with a needle tip, can be fixed adjacent to the mounted stent 10 and ejection of a coating substance can be controlled by the CNC controller. The needle tip can have an outer diameter of about 0.02 mm (0.0008in.) to about 0.038 mm (0.0015 in.) and an inner diameter from about 0.005 mm (0.0002 in.) to about 0.02 mm (0.0009 in.). The CNC controller then causes ejection of coating 20 in a liquid state from the needle tip into recessed volume 18 and simultaneously moves stent 10 longitudinally to spread coating 20 evenly in recessed volume 18. Once recessed volume 18 of segment 16 is coated with a desired volume of coating 20, ejection of the coating substance ceases and stent 10 can be moved until the next uncoated recessed volume 18 is adjacent to the needle tip of the fluid applicator device. The process can repeat until all the recessed volumes 18 are coated. The needle tip should also be capable of being raised and lowered relative to stent 10 by the CNC controller particularly when coating small volumes necessitates direct contact between the needle tip and stent 10.
  • Alternatively, coating 20 can be deposited in recessed volumes 18 by crimping stent 10 onto a mandrel covered with a soft material (for examples, having a D hardness rating of about 20 to about 50, such as silicon foam, neoprene, santoprene, or a closed cell foam). In a relaxed state, the soft material can have, for example, a soft material thickness of at least the thickness of strut 12. The mandrel and stent 10 can then be dipped into the coating substance or the coating substance can be sprayed onto stent 10. The mandrel and stent 10 can then be pulled through an orifice with a clearance around strut 12 of less than about 0.003 mm (0.0001 in.), more narrowly less than about 0.001 mm (0.00005 in.). Stent 10 can also be pulled over a reamer to scrape off excess coating substance.
  • In accordance with another embodiment of the invention, masking techniques as is known to a person having ordinary skill in the art can be used to deposit coating 20 in recessed volumes 18 of segment 16.
  • While particular embodiments of the present invention have been shown and described, it will be obvious to those having ordinary skill in the art that changes and modifications can be made without departing from this invention. Therefore, the appended claims are to encompass within their scope all such changes and modifications as they fall within the true spirit and scope of the invention.

Claims (16)

1. A stent comprising a strut segment including a first recess on an outer surface of the strut and a second recess on an inner surface of the strut, the recesses disposed on opposite sides of the strut segment from each other, wherein the recesses carry a coating substance.
2. The stent of claim 1, wherein the coating substance includes a polymeric material.
3. The stent of claim 1, wherein a remaining portion of the strut segment is free from any coating.
4. The stent of claim 1, wherein the coating substance includes a drug.
5. The stent of claim 1, wherein the strut segment has a rectangular, triangular, oval or circular cross-sectional shape.
6. The stent of claim 1, wherein an outer surface of the coating substance does not extend beyond the surface of the strut segment.
7. A method of manufacturing a stent, comprising depositing a coating on a stent, the stent including a strut segment having a First recess on an outer surface of the strut and a second recess on an inner surface of the strut, the recesses disposed on opposite sides of the strut segment from each other.
8. The method of claim 7, wherein the coating includes a polymeric material.
9. The method of claim 7, wherein a remaining portion of the strut segment is free from any coating.
10. The method of claim 7, wherein the coating includes a drug.
11. The method of claim 7, wherein the strut segment has a rectangular, triangular, oval or circular cross-sectional shape.
12. The method of claim 7, wherein an outer surface of the coating does not extend beyond the surface of the strut segment.
13. A method of manufacturing a stent, comprising:
depositing a coating on a stent, the stent including a strut having a first segment, a second segment and a third segment located between the first and second segments, wherein the transverse cross-sectional area of the third segment is less than the transverse cross-sectional area of the first segment and the second segment, and wherein the strut includes a linear segment extending into a curved or bent segment, the first, second and third segments defining a part of the linear segment of the strut, wherein the curved or bent segment includes a notch carved out from the surface of the strut; and
removing the coating off of the first and second segments so that the coating remains on the third segment.
14. The method of claim 13, wherein the coating includes a drug.
15. The method of claim 13, wherein the strut has a rectangular, triangular, oval or circular cross-sectional shape.
16. The method of claim 13, wherein an outer surface of the coating does not extend beyond an outer surface of the strut.
US11/546,203 2002-09-30 2006-10-10 Drug eluting stent Abandoned US20070032856A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/546,203 US20070032856A1 (en) 2002-09-30 2006-10-10 Drug eluting stent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/262,150 US7135038B1 (en) 2002-09-30 2002-09-30 Drug eluting stent
US11/546,203 US20070032856A1 (en) 2002-09-30 2006-10-10 Drug eluting stent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/262,150 Division US7135038B1 (en) 2002-09-30 2002-09-30 Drug eluting stent

Publications (1)

Publication Number Publication Date
US20070032856A1 true US20070032856A1 (en) 2007-02-08

Family

ID=37397616

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/262,150 Expired - Lifetime US7135038B1 (en) 2002-09-30 2002-09-30 Drug eluting stent
US11/546,203 Abandoned US20070032856A1 (en) 2002-09-30 2006-10-10 Drug eluting stent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/262,150 Expired - Lifetime US7135038B1 (en) 2002-09-30 2002-09-30 Drug eluting stent

Country Status (1)

Country Link
US (2) US7135038B1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060161243A1 (en) * 2004-12-09 2006-07-20 Cook Group Patent Office S-shaped stent design
US20080260936A1 (en) * 2007-04-20 2008-10-23 Matt Heidner Spread coating a medical device
US20100100177A1 (en) * 2008-10-20 2010-04-22 Advanced Medical Optics, Inc. Multifocal Intraocular Lens
US20110208290A1 (en) * 2008-02-26 2011-08-25 Helmut Straubinger Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US8834561B2 (en) 2005-10-28 2014-09-16 Jenavalve Technology Gmbh Device for the implantation and fixation of prosthetic valves
US9744031B2 (en) 2010-05-25 2017-08-29 Jenavalve Technology, Inc. Prosthetic heart valve and endoprosthesis comprising a prosthetic heart valve and a stent
US9867699B2 (en) 2008-02-26 2018-01-16 Jenavalve Technology, Inc. Endoprosthesis for implantation in the heart of a patient
WO2019176790A1 (en) * 2018-03-15 2019-09-19 テルモ株式会社 Stent
US11065138B2 (en) 2016-05-13 2021-07-20 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
US11185405B2 (en) 2013-08-30 2021-11-30 Jenavalve Technology, Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US11197754B2 (en) 2017-01-27 2021-12-14 Jenavalve Technology, Inc. Heart valve mimicry
US11337800B2 (en) 2015-05-01 2022-05-24 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
US11357624B2 (en) 2007-04-13 2022-06-14 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US11517431B2 (en) 2005-01-20 2022-12-06 Jenavalve Technology, Inc. Catheter system for implantation of prosthetic heart valves
US11564794B2 (en) 2008-02-26 2023-01-31 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
GB0020491D0 (en) 2000-08-18 2000-10-11 Angiomed Ag Stent with attached element and method of making such a stent
US6764505B1 (en) 2001-04-12 2004-07-20 Advanced Cardiovascular Systems, Inc. Variable surface area stent
US7169178B1 (en) * 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
EP1670545B1 (en) * 2003-07-22 2012-02-22 Corazon Technologies, Inc. Devices for treating aortic valve stenosis
US20050208093A1 (en) 2004-03-22 2005-09-22 Thierry Glauser Phosphoryl choline coating compositions
US20060079956A1 (en) * 2004-09-15 2006-04-13 Conor Medsystems, Inc. Bifurcation stent with crushable end and method for delivery of a stent to a bifurcation
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
ES2764992T3 (en) 2005-04-04 2020-06-05 Flexible Stenting Solutions Inc Flexible stent
US20070055352A1 (en) * 2005-09-07 2007-03-08 Wendy Naimark Stent with pockets for containing a therapeutic agent
US20070135896A1 (en) * 2005-12-13 2007-06-14 Robert Burgermeister Polymeric stent having modified molecular structures in the flexible connectors and the radial struts of the hoops
US20070135895A1 (en) * 2005-12-13 2007-06-14 Robert Burgermeister Polymeric stent having modified molecular structures in both the hoops and selected segments of the flexible connectors
US20070135894A1 (en) * 2005-12-13 2007-06-14 Robert Burgermeister Polymeric stent having modified molecular structures in the flexible connections
US8263103B2 (en) * 2006-01-31 2012-09-11 Boston Scientific Scimed, Inc. Medical articles containing biodegradable polymers and acid-neutralizing cationic species
US20070254003A1 (en) * 2006-05-01 2007-11-01 Pu Zhou Non-sticky coatings with therapeutic agents for medical devices
GB0609841D0 (en) 2006-05-17 2006-06-28 Angiomed Ag Bend-capable tubular prosthesis
GB0609911D0 (en) * 2006-05-18 2006-06-28 Angiomed Ag Bend-capable stent prosthesis
US20070288085A1 (en) * 2006-05-31 2007-12-13 Furst Joseph G Absorbable medical devices with specific design features
US8685430B1 (en) 2006-07-14 2014-04-01 Abbott Cardiovascular Systems Inc. Tailored aliphatic polyesters for stent coatings
US7651523B2 (en) * 2006-07-24 2010-01-26 Cook Incorporated Intraluminal device with flexible regions
US8952123B1 (en) 2006-08-02 2015-02-10 Abbott Cardiovascular Systems Inc. Dioxanone-based copolymers for implantable devices
GB0616729D0 (en) * 2006-08-23 2006-10-04 Angiomed Ag Method of welding a component to a shape memory alloy workpiece
GB0616999D0 (en) * 2006-08-29 2006-10-04 Angiomed Ag Annular mesh
EP2063824B1 (en) * 2006-09-07 2020-10-28 Angiomed GmbH & Co. Medizintechnik KG Helical implant having different ends
GB0622465D0 (en) * 2006-11-10 2006-12-20 Angiomed Ag Stent
GB0624419D0 (en) * 2006-12-06 2007-01-17 Angiomed Ag Stenting ring with marker
WO2008088537A2 (en) * 2006-12-20 2008-07-24 Boston Scientific Limited Stent with a coating for delivering a therapeutic agent
US20080175882A1 (en) * 2007-01-23 2008-07-24 Trollsas Mikael O Polymers of aliphatic thioester
GB0703379D0 (en) * 2007-02-21 2007-03-28 Angiomed Ag Stent with radiopaque marker
US8974514B2 (en) * 2007-03-13 2015-03-10 Abbott Cardiovascular Systems Inc. Intravascular stent with integrated link and ring strut
GB0706499D0 (en) * 2007-04-03 2007-05-09 Angiomed Ag Bendable stent
TW200840553A (en) * 2007-04-12 2008-10-16 Jung-Tang Huang A fabrication method for drug-eluting stent with medicine-compatible filling mechanism
US10155881B2 (en) * 2007-05-30 2018-12-18 Abbott Cardiovascular Systems Inc. Substituted polycaprolactone for coating
US9737638B2 (en) * 2007-06-20 2017-08-22 Abbott Cardiovascular Systems, Inc. Polyester amide copolymers having free carboxylic acid pendant groups
US7927621B2 (en) * 2007-06-25 2011-04-19 Abbott Cardiovascular Systems Inc. Thioester-ester-amide copolymers
US20090004243A1 (en) 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
US7988723B2 (en) 2007-08-02 2011-08-02 Flexible Stenting Solutions, Inc. Flexible stent
GB0717481D0 (en) * 2007-09-07 2007-10-17 Angiomed Ag Self-expansible stent with radiopaque markers
US9814553B1 (en) 2007-10-10 2017-11-14 Abbott Cardiovascular Systems Inc. Bioabsorbable semi-crystalline polymer for controlling release of drug from a coating
EP3505142B1 (en) 2007-10-19 2020-10-28 CeloNova Biosciences, Inc. Implantable and lumen-supporting stents
US20090104241A1 (en) * 2007-10-23 2009-04-23 Pacetti Stephen D Random amorphous terpolymer containing lactide and glycolide
US20090110713A1 (en) * 2007-10-31 2009-04-30 Florencia Lim Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
US7833266B2 (en) 2007-11-28 2010-11-16 Boston Scientific Scimed, Inc. Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment
US7972373B2 (en) * 2007-12-19 2011-07-05 Advanced Technologies And Regenerative Medicine, Llc Balloon expandable bioabsorbable stent with a single stress concentration region interconnecting adjacent struts
US9370437B2 (en) * 2007-12-26 2016-06-21 Cook Medical Technologies Llc Stent having less invasive ends
US20090186068A1 (en) * 2008-01-18 2009-07-23 Chameleon Scientific Corporation Atomic plasma deposited coatings for drug release
ES2371380T3 (en) * 2008-01-24 2011-12-30 Boston Scientific Scimed, Inc. STENT TO SUPPLY A THERAPEUTIC AGENT FROM A SIDE SURFACE OF A STENT STEM.
WO2009108716A2 (en) 2008-02-27 2009-09-03 University Of Louisville Research Foundation Synthetic peptides
US8128983B2 (en) 2008-04-11 2012-03-06 Abbott Cardiovascular Systems Inc. Coating comprising poly(ethylene glycol)-poly(lactide-glycolide-caprolactone) interpenetrating network
US20090297584A1 (en) * 2008-04-18 2009-12-03 Florencia Lim Biosoluble coating with linear over time mass loss
US8916188B2 (en) 2008-04-18 2014-12-23 Abbott Cardiovascular Systems Inc. Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block
US8114151B2 (en) * 2008-05-08 2012-02-14 Boston Scientific Scimed, Inc. Stent with tabs and holes for drug delivery
US8697113B2 (en) 2008-05-21 2014-04-15 Abbott Cardiovascular Systems Inc. Coating comprising a terpolymer comprising caprolactone and glycolide
US7951193B2 (en) 2008-07-23 2011-05-31 Boston Scientific Scimed, Inc. Drug-eluting stent
US9149376B2 (en) 2008-10-06 2015-10-06 Cordis Corporation Reconstrainable stent delivery system
US20100100170A1 (en) * 2008-10-22 2010-04-22 Boston Scientific Scimed, Inc. Shape memory tubular stent with grooves
CN101732114B (en) * 2008-11-04 2014-07-30 上海微创医疗器械(集团)有限公司 Coronary artery stent with medicine carrying grooves
US8697110B2 (en) * 2009-05-14 2014-04-15 Abbott Cardiovascular Systems Inc. Polymers comprising amorphous terpolymers and semicrystalline blocks
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
WO2013156871A2 (en) 2012-04-17 2013-10-24 University College Dublin, National University Of Ireland, Dublin Thromboxane receptor antagonists
EP2838519B1 (en) 2012-04-17 2017-11-22 University College Dublin National University Of Ireland, Dublin Methods and compounds for treating proliferative disorders and viral infections
US9486559B2 (en) * 2013-05-07 2016-11-08 Abbott Cardiovascular Systems Inc. Methods of treatment with a bioresorbable scaffold for neurologic drug delivery
CN106535826A (en) 2014-06-24 2017-03-22 怡康医疗股份有限公司 Improved metal alloys for medical devices
US9381103B2 (en) * 2014-10-06 2016-07-05 Abbott Cardiovascular Systems Inc. Stent with elongating struts
US9932304B2 (en) 2015-06-16 2018-04-03 University College Dublin, National University Of Ireland, Dublin Thromboxane receptor antagonists
WO2017151548A1 (en) 2016-03-04 2017-09-08 Mirus Llc Stent device for spinal fusion
US10849769B2 (en) * 2017-08-23 2020-12-01 Vesper Medical, Inc. Non-foreshortening stent

Citations (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459252A (en) * 1975-05-09 1984-07-10 Macgregor David C Method of forming a small bore flexible vascular graft involving eluting solvent-elutable particles from a polymeric tubular article
US5059211A (en) * 1987-06-25 1991-10-22 Duke University Absorbable vascular stent
US5163952A (en) * 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
US5282823A (en) * 1992-03-19 1994-02-01 Medtronic, Inc. Intravascular radially expandable stent
US5342348A (en) * 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5425739A (en) * 1989-03-09 1995-06-20 Avatar Design And Development, Inc. Anastomosis stent and stent selection system
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5514154A (en) * 1991-10-28 1996-05-07 Advanced Cardiovascular Systems, Inc. Expandable stents
US5527337A (en) * 1987-06-25 1996-06-18 Duke University Bioabsorbable stent and method of making the same
US5569295A (en) * 1993-12-28 1996-10-29 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US5629077A (en) * 1994-06-27 1997-05-13 Advanced Cardiovascular Systems, Inc. Biodegradable mesh and film stent
US5700286A (en) * 1994-12-13 1997-12-23 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
US5713949A (en) * 1996-08-06 1998-02-03 Jayaraman; Swaminathan Microporous covered stents and method of coating
US5722984A (en) * 1996-01-16 1998-03-03 Iso Stent, Inc. Antithrombogenic radioactive coating for an intravascular stent
US5769883A (en) * 1991-10-04 1998-06-23 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5843172A (en) * 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US5855600A (en) * 1997-08-01 1999-01-05 Inflow Dynamics Inc. Flexible implantable stent with composite design
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US5891108A (en) * 1994-09-12 1999-04-06 Cordis Corporation Drug delivery stent
US5972027A (en) * 1997-09-30 1999-10-26 Scimed Life Systems, Inc Porous stent drug delivery system
US5980972A (en) * 1996-12-20 1999-11-09 Schneider (Usa) Inc Method of applying drug-release coatings
US6042606A (en) * 1997-09-29 2000-03-28 Cook Incorporated Radially expandable non-axially contracting surgical stent
US6071305A (en) * 1996-11-25 2000-06-06 Alza Corporation Directional drug delivery stent and method of use
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6120536A (en) * 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US6129755A (en) * 1998-01-09 2000-10-10 Nitinol Development Corporation Intravascular stent having an improved strut configuration
US6171334B1 (en) * 1998-06-17 2001-01-09 Advanced Cardiovascular Systems, Inc. Expandable stent and method of use
US6203569B1 (en) * 1996-01-04 2001-03-20 Bandula Wijay Flexible stent
US6206915B1 (en) * 1998-09-29 2001-03-27 Medtronic Ave, Inc. Drug storing and metering stent
US6254632B1 (en) * 2000-09-28 2001-07-03 Advanced Cardiovascular Systems, Inc. Implantable medical device having protruding surface structures for drug delivery and cover attachment
US6273908B1 (en) * 1997-10-24 2001-08-14 Robert Ndondo-Lay Stents
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6273910B1 (en) * 1999-03-11 2001-08-14 Advanced Cardiovascular Systems, Inc. Stent with varying strut geometry
US6287628B1 (en) * 1999-09-03 2001-09-11 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6299604B1 (en) * 1998-08-20 2001-10-09 Cook Incorporated Coated implantable medical device
US6355063B1 (en) * 2000-01-20 2002-03-12 Impra, Inc. Expanded PTFE drug delivery graft
US6379381B1 (en) * 1999-09-03 2002-04-30 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6395326B1 (en) * 2000-05-31 2002-05-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for depositing a coating onto a surface of a prosthesis
US6416543B1 (en) * 1997-06-20 2002-07-09 Cathnet-Science S.A. Expandable stent with variable thickness
US6506437B1 (en) * 2000-10-17 2003-01-14 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device having depots formed in a surface thereof
US6551353B1 (en) * 1997-10-28 2003-04-22 Hills, Inc. Synthetic fibers for medical use and method of making the same
US6887266B2 (en) * 2002-11-14 2005-05-03 Synecor, Llc Endoprostheses and methods of manufacture
US6979347B1 (en) * 2000-10-23 2005-12-27 Advanced Cardiovascular Systems, Inc. Implantable drug delivery prosthesis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4191989A (en) 1988-08-24 1990-03-23 Marvin J. Slepian Biodegradable polymeric endoluminal sealing
CA2026604A1 (en) * 1989-10-02 1991-04-03 Rodney G. Wolff Articulated stent
IT1276342B1 (en) 1993-06-04 1997-10-30 Ist Naz Stud Cura Dei Tumori METAL STENT COVERED WITH BIOCOMPATIBLE POLYMERIC MATERIAL
DE69510986T2 (en) * 1994-04-25 1999-12-02 Advanced Cardiovascular System Radiation-opaque stent markings
US6783543B2 (en) 2000-06-05 2004-08-31 Scimed Life Systems, Inc. Intravascular stent with increasing coating retaining capacity
US6174329B1 (en) * 1996-08-22 2001-01-16 Advanced Cardiovascular Systems, Inc. Protective coating for a stent with intermediate radiopaque coating
US6086611A (en) * 1997-09-25 2000-07-11 Ave Connaught Bifurcated stent
US7208010B2 (en) * 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
JPH11299901A (en) 1998-04-16 1999-11-02 Johnson & Johnson Medical Kk Stent and its manufacture
WO2000000238A1 (en) 1998-06-26 2000-01-06 Quanam Medical Corporation Topoisomerase inhibitors for prevention of restenosis
CA2376069A1 (en) 1999-06-30 2001-01-04 Orlando M. Padilla Variable thickness stent and method of manufacture thereof
US6540774B1 (en) * 1999-08-31 2003-04-01 Advanced Cardiovascular Systems, Inc. Stent design with end rings having enhanced strength and radiopacity
WO2001091918A1 (en) 2000-05-31 2001-12-06 Advanced Cardiovascular Systems, Inc. An apparatus and method for forming a coating onto a surface of a prosthesis
US6764507B2 (en) * 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
US6605110B2 (en) * 2001-06-29 2003-08-12 Advanced Cardiovascular Systems, Inc. Stent with enhanced bendability and flexibility

Patent Citations (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459252A (en) * 1975-05-09 1984-07-10 Macgregor David C Method of forming a small bore flexible vascular graft involving eluting solvent-elutable particles from a polymeric tubular article
US5306286A (en) * 1987-06-25 1994-04-26 Duke University Absorbable stent
US5059211A (en) * 1987-06-25 1991-10-22 Duke University Absorbable vascular stent
US5527337A (en) * 1987-06-25 1996-06-18 Duke University Bioabsorbable stent and method of making the same
US5425739A (en) * 1989-03-09 1995-06-20 Avatar Design And Development, Inc. Anastomosis stent and stent selection system
US5163952A (en) * 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
US5769883A (en) * 1991-10-04 1998-06-23 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5514154A (en) * 1991-10-28 1996-05-07 Advanced Cardiovascular Systems, Inc. Expandable stents
US5603721A (en) * 1991-10-28 1997-02-18 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
US5282823A (en) * 1992-03-19 1994-02-01 Medtronic, Inc. Intravascular radially expandable stent
US5342348A (en) * 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5569295A (en) * 1993-12-28 1996-10-29 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
US5766710A (en) * 1994-06-27 1998-06-16 Advanced Cardiovascular Systems, Inc. Biodegradable mesh and film stent
US5629077A (en) * 1994-06-27 1997-05-13 Advanced Cardiovascular Systems, Inc. Biodegradable mesh and film stent
US5891108A (en) * 1994-09-12 1999-04-06 Cordis Corporation Drug delivery stent
US5700286A (en) * 1994-12-13 1997-12-23 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US6120536A (en) * 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US6203569B1 (en) * 1996-01-04 2001-03-20 Bandula Wijay Flexible stent
US5722984A (en) * 1996-01-16 1998-03-03 Iso Stent, Inc. Antithrombogenic radioactive coating for an intravascular stent
US5713949A (en) * 1996-08-06 1998-02-03 Jayaraman; Swaminathan Microporous covered stents and method of coating
US6071305A (en) * 1996-11-25 2000-06-06 Alza Corporation Directional drug delivery stent and method of use
US5980972A (en) * 1996-12-20 1999-11-09 Schneider (Usa) Inc Method of applying drug-release coatings
US5843172A (en) * 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6416543B1 (en) * 1997-06-20 2002-07-09 Cathnet-Science S.A. Expandable stent with variable thickness
US5855600A (en) * 1997-08-01 1999-01-05 Inflow Dynamics Inc. Flexible implantable stent with composite design
US6042606A (en) * 1997-09-29 2000-03-28 Cook Incorporated Radially expandable non-axially contracting surgical stent
US5972027A (en) * 1997-09-30 1999-10-26 Scimed Life Systems, Inc Porous stent drug delivery system
US6273908B1 (en) * 1997-10-24 2001-08-14 Robert Ndondo-Lay Stents
US6551353B1 (en) * 1997-10-28 2003-04-22 Hills, Inc. Synthetic fibers for medical use and method of making the same
US6129755A (en) * 1998-01-09 2000-10-10 Nitinol Development Corporation Intravascular stent having an improved strut configuration
US6171334B1 (en) * 1998-06-17 2001-01-09 Advanced Cardiovascular Systems, Inc. Expandable stent and method of use
US6299604B1 (en) * 1998-08-20 2001-10-09 Cook Incorporated Coated implantable medical device
US6206915B1 (en) * 1998-09-29 2001-03-27 Medtronic Ave, Inc. Drug storing and metering stent
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6273910B1 (en) * 1999-03-11 2001-08-14 Advanced Cardiovascular Systems, Inc. Stent with varying strut geometry
US6287628B1 (en) * 1999-09-03 2001-09-11 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6379381B1 (en) * 1999-09-03 2002-04-30 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6355063B1 (en) * 2000-01-20 2002-03-12 Impra, Inc. Expanded PTFE drug delivery graft
US6395326B1 (en) * 2000-05-31 2002-05-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for depositing a coating onto a surface of a prosthesis
US6254632B1 (en) * 2000-09-28 2001-07-03 Advanced Cardiovascular Systems, Inc. Implantable medical device having protruding surface structures for drug delivery and cover attachment
US6506437B1 (en) * 2000-10-17 2003-01-14 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device having depots formed in a surface thereof
US6979347B1 (en) * 2000-10-23 2005-12-27 Advanced Cardiovascular Systems, Inc. Implantable drug delivery prosthesis
US6887266B2 (en) * 2002-11-14 2005-05-03 Synecor, Llc Endoprostheses and methods of manufacture

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060161243A1 (en) * 2004-12-09 2006-07-20 Cook Group Patent Office S-shaped stent design
US7655033B2 (en) * 2004-12-09 2010-02-02 Med Institute, Inc. S-shaped stent design
US11517431B2 (en) 2005-01-20 2022-12-06 Jenavalve Technology, Inc. Catheter system for implantation of prosthetic heart valves
US11116628B2 (en) 2005-10-28 2021-09-14 Jenavalve Technology, Inc. Device for the implantation and fixation of prosthetic valves
US9855142B2 (en) 2005-10-28 2018-01-02 JenaValve Technologies, Inc. Device for the implantation and fixation of prosthetic valves
US10363134B2 (en) 2005-10-28 2019-07-30 Jenavalve Technology, Inc. Device for the implantation and fixation of prosthetic valves
US8834561B2 (en) 2005-10-28 2014-09-16 Jenavalve Technology Gmbh Device for the implantation and fixation of prosthetic valves
US9044320B2 (en) 2005-10-28 2015-06-02 Jenavalve Technology Gmbh Device for the implantation and fixation of prosthetic valves
USRE45790E1 (en) 2005-10-28 2015-11-03 Jenavalve Technology Gmbh Device for the implantation and fixation of prosthetic valves
USRE45962E1 (en) 2005-10-28 2016-04-05 Jenavalve Technology Gmbh Device for the implantation and fixation of prosthetic valves
US9402717B2 (en) 2005-10-28 2016-08-02 Jenavalve Technology, Inc. Device for the implantation and fixation of prosthetic valves
US11357624B2 (en) 2007-04-13 2022-06-14 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US8119151B2 (en) * 2007-04-20 2012-02-21 Boston Scientific Scimed, Inc. Spread coating a medical device
US20080260936A1 (en) * 2007-04-20 2008-10-23 Matt Heidner Spread coating a medical device
US9867699B2 (en) 2008-02-26 2018-01-16 Jenavalve Technology, Inc. Endoprosthesis for implantation in the heart of a patient
US10993805B2 (en) 2008-02-26 2021-05-04 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US9439759B2 (en) 2008-02-26 2016-09-13 Jenavalve Technology, Inc. Endoprosthesis for implantation in the heart of a patient
US9987133B2 (en) 2008-02-26 2018-06-05 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US10154901B2 (en) 2008-02-26 2018-12-18 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US8790395B2 (en) 2008-02-26 2014-07-29 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11564794B2 (en) 2008-02-26 2023-01-31 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US20110208290A1 (en) * 2008-02-26 2011-08-25 Helmut Straubinger Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US10702382B2 (en) 2008-02-26 2020-07-07 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11154398B2 (en) 2008-02-26 2021-10-26 JenaValve Technology. Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US8465540B2 (en) * 2008-02-26 2013-06-18 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis
US20100100177A1 (en) * 2008-10-20 2010-04-22 Advanced Medical Optics, Inc. Multifocal Intraocular Lens
US9744031B2 (en) 2010-05-25 2017-08-29 Jenavalve Technology, Inc. Prosthetic heart valve and endoprosthesis comprising a prosthetic heart valve and a stent
US10603164B2 (en) 2010-05-25 2020-03-31 Jenavalve Technology, Inc. Prosthetic heart valve and endoprosthesis comprising a prosthetic heart valve and a stent
US11589981B2 (en) 2010-05-25 2023-02-28 Jenavalve Technology, Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
US11185405B2 (en) 2013-08-30 2021-11-30 Jenavalve Technology, Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US11337800B2 (en) 2015-05-01 2022-05-24 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
US11065138B2 (en) 2016-05-13 2021-07-20 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
US11197754B2 (en) 2017-01-27 2021-12-14 Jenavalve Technology, Inc. Heart valve mimicry
WO2019176790A1 (en) * 2018-03-15 2019-09-19 テルモ株式会社 Stent

Also Published As

Publication number Publication date
US7135038B1 (en) 2006-11-14

Similar Documents

Publication Publication Date Title
US7135038B1 (en) Drug eluting stent
US6709514B1 (en) Rotary coating apparatus for coating implantable medical devices
US7666223B2 (en) Stent with drug coating
US8343206B2 (en) Drug-eluting stent and delivery system with tapered stent in shoulder region
EP1684821B1 (en) Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US8382817B2 (en) Endoprostheses for peripheral arteries and other body vessels
US8974514B2 (en) Intravascular stent with integrated link and ring strut
US20040172127A1 (en) Modular stent having polymer bridges at modular unit contact sites
US20100030183A1 (en) Method of treating vascular disease at a bifurcated vessel using a coated balloon
US20070027523A1 (en) Method of treating vascular disease at a bifurcated vessel using coated balloon
EP2739405B1 (en) Multiple stent design and coating thereof
WO2004032804A1 (en) Rate limiting barriers for implantable medical devices
WO2010093800A2 (en) Multiple drug delivery from a balloon and a prosthesis
US20090076590A1 (en) Endoprostheses with strut pattern having multiple stress relievers
WO2022176792A1 (en) Stent and method for manufacturing stent
US10010655B2 (en) Drug delivery device, method, and system for administration of dual antiplatelet therapy

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION